Table 3 The percent of lung lobe involvement (*p < 0.005 defines a significant difference)
From: Prognostic impact of CT severity score in childhood cancer with SARS-CoV-2
| Â | All patients (N = 64) | Mild (N = 45) | Moderate/severe (N = 19) | P value |
|---|---|---|---|---|
Right upper lobe | 0.001* | |||
 0 | 23 (35.9%) | 21 (46.68%) | 2 (10.5%) | |
 1 | 23 (35.9%) | 16 (35.5%) | 7 (36.8%) | |
 2 | 8 (12.5%) | 4 (8.8 %) | 4 (21%) | |
 3 | 2 (3.12%) | 1 (2.2%) | 1 (5.2%) | |
 4 | 8 (12.5%) | 3 (6.6 %) | 5 (26.3%) | |
Right middle lobe | 0.001* | |||
 0 | 34 (53.1%) | 29 (64.4%) | 5 (26.3%) | |
 1 | 15 (23.4%) | 10 (22.2%) | 5 (26.3%) | |
 2 | 8 (12.5%) | 4 (8.8 %) | 4 (21%) | |
 3 | 3 (4.7%) | 1 (2.2%) | 2 (10.5%) | |
 4 | 4 (6.3%) | 1 (2.2%) | 3 (15.7%) | |
Left upper lobe | 0.002* | |||
 0 | 28 (43.75%) | 24 (53.3%) | 4 (21%) | |
 1 | 18 (28.12%) | 13 (28.8%) | 5 (26.3%) | |
 2 | 8 (12.5%) | 4 (8.8%) | 4 (21%) | |
 3 | 5 (7.81%) | 3 (6.6%) | 2 (10.5%) | |
 4 | 5 (7.81%) | 1 (2.2%) | 4 (21%) | |
Right lower lobe | 0.012* | |||
 0 | 9 (14.1%) | 8 (17.7%) | 1 (5.2%) | |
 1 | 20 (31.2%) | 15 (33.3%) | 5 (26.3%) | |
 2 | 15 (23.4%) | 13 (28.8%) | 2 (10.5%) | |
 3 | 12 (18.8%) | 6 (13.3) | 6 (31.5%) | |
 4 | 5 (7.81%) | 5 (26.3%) | 5 (26.3%) | |
Left lower lobe | 0.006* | |||
 0 | 11 (17.2%) | 9 (20%) | 2 (10.5%) | |
 1 | 23 (35.9%) | 19 (42.2%) | 4 (21%) | |
 2 | 13 (20.3%) | 10 (22.2%) | 3 (15.7%) | |
 3 | 9 (14.1%) | 5 (11.1%) | 4 (21%) | |
 4 | 8 (12.5%) | 2 (4.4) % | 6 (31.5%) | |